India, June 1 -- Supriya Lifescience has built a strong presence in niche APIs. How did the company perform during FY25-26, and how do you see your product portfolio evolving to meet changing global pharmaceutical demands?

Following a strong FY25 where we achieved Rs 706.3 crore in total revenue and a 57.8 per cent surge in net profit, FY26 has demonstrated tremendous momentum. While full-year audited numbers are being finalised, our Q3 FY26 results underscore our operational strength. In Q3, we reported 11.2 per cent year-on-year revenue growth to Rs 206.44 crore, with Profit After Tax rising to Rs 49.68 crore. This followed a stellar Q2 FY26 where revenue surged over 20 per cent to Rs 199.83 crore. Looking ahead, management remains hig...